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IMPORTANCE Mutations of the glucocerebrosidase gene, GBA1 (OMIM 606463), are the
most important risk factor for Parkinson disease (PD). In vitro and in vivo studies have
reported that ambroxol increases β-glucocerebrosidase (GCase) enzyme activity and
reduces α-synuclein levels. These observations support a potential role for ambroxol
therapy in modifying a relevant pathogenetic pathway in PD.
OBJECTIVE To assess safety, tolerability, cerebrospinal fluid (CSF) penetration, and target
engagement of ambroxol therapy with GCase in patients with PD with and without
GBA1 mutations.
INTERVENTIONS An escalating dose of oral ambroxol to 1.26 g per day.
DESIGN, SETTING, AND PARTICIPANTS This single-center open-label noncontrolled clinical trial
was conducted between January 11, 2017, and April 25, 2018, at the Leonard Wolfson
Experimental Neuroscience Centre, a dedicated clinical research facility and part of the
University College London Queen Square Institute of Neurology in London, United Kingdom.
Participants were recruited from established databases at the Royal Free London Hospital
and National Hospital for Neurology and Neurosurgery in London. Twenty-four patients with
moderate PD were evaluated for eligibility, and 23 entered the study. Of those, 18 patients
completed the study; 1 patient was excluded (failed lumbar puncture), and 4 patients
withdrew (predominantly lumbar puncture–related complications). All data analyses were
performed from November 1 to December 14, 2018.
MAIN OUTCOMES AND MEASURES Primary outcomes at 186 days were the detection
of ambroxol in the CSF and a change in CSF GCase activity.
RESULTS Of the 18 participants (15 men [83.3%]; mean [SD] age, 60.2 [9.7] years) who
completed the study, 17 (8 with GBA1 mutations and 9 without GBA1 mutations) were
included in the primary analysis. Between days 0 and 186, a 156-ng/mL increase in the level
of ambroxol in CSF (lower 95% confidence limit, 129 ng/mL; P < .001) was observed. The CSF
GCase activity decreased by 19% (0.059 nmol/mL per hour; 95% CI, –0.115 to –0.002;
P = .04). The ambroxol therapy was well tolerated, with no serious adverse events. An
increase of 50 pg/mL (13%) in the CSF α-synuclein concentration (95% CI, 14-87; P = .01) and
an increase of 88 ng/mol (35%) in the CSF GCase protein levels (95% CI, 40-137; P = .002)
were observed. Mean (SD) scores on part 3 of the Movement Disorders Society Unified
Parkinson Disease Rating Scale decreased (ie, improved) by 6.8 (7.1) points (95% CI, –10.4 to
–3.1; P = .001). These changes were observed in patients with and without GBA1 mutations.
CONCLUSIONS AND RELEVANCE The study results suggest that ambroxol therapy was safe and
well tolerated; CSF penetration and target engagement of ambroxol were achieved, and CSF
α-synuclein levels were increased. Placebo-controlled clinical trials are needed to examine
whether ambroxol therapy is associated with changes in the natural progression of PD.
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M utations in the glucocerebrosidase gene, GBA1(OMIM 606463), cause the autosomal recessivelysosomal storage disorder, Gaucher disease.1
These mutations are the most important genetic risk factor
for Parkinson disease (PD),2 exhibiting penetrance of 10% to
30%.3,4 They are present in 5% to 15% of Caucasian patients
with PD, 25% of Ashkenazi Jewish patients with PD, and 1%
of individuals without PD.5
In GBA1 cel l and animal models, an inc reased
α-synuclein accumulation and a reciprocal relationship
between α-synuclein levels and β-glucocerebrosidase
(GCase) enzyme activity have been reported.6-11 Although
GCase activity is reduced in the brains of patients with PD
with and without GBA1 mutations, it is lower in those with
the mutations.12 Reduced GCase activity in the brain is asso-
ciated with increased levels of α-synuclein.13 In addition,
GCase activity is decreased in the cerebrospinal fluid (CSF)
of patients with PD with and without GBA1 mutations com-
pared with controls.14 Upregulation of brain cytosolic/
lysosomal GCase activity may reduce α-synuclein levels,
mediating a neuroprotective effect in patients with PD both
with and without GBA1 mutations.15-17
Ambroxol therapy has been safely used as a cough linc-
tus since the 1970s (summary of product characteristics in
eMethods 1 in Supplement 2). Its principal adverse effects
are gastrointestinal disturbance and a small risk of anaphy-
laxis. A high-throughput compound evaluation indicated
that ambroxol delivered a pH-dependent increase in GCase
activity.18
Ambroxol administration has also been reported to
increase GCase activity and reduce α-synuclein levels in
vitro and in vivo.6-11 Ambroxol is an inhibitory chaperone
that mobilizes the sequestered mutant GCase from the
endoplasmic reticulum by binding to and inhibiting the
enzyme active site, inducing conformational change and
facilitating transportation to the lysosome.19,20 In the acidic
lysosome, ambroxol is eluted, allowing normal catalysis to
resume and restoring lysosomal function.
Ambroxol may modulate α-synuclein levels through
several mechanisms. The GCase may have a direct role in
α-synuclein protein disposal,21,22 and ambroxol has been
shown to upregulate GCase expression through the tran-
scription factor EB pathway and stimulation of lysosomal
exocytosis.9,23 Alternatively, GBA1 mutations may interrupt
physiologic posttranslational folding, preventing transpor-
tation of the enzyme to the lysosome.19,20,24,25 This inter-
ruption appears to result in sequestration in the endoplas-
mic reticulum and an unfolded protein response that may
induce α-synuclein aggregation.24 Evidence also suggests
that ambroxol corrects posttranslational folding, mitigating
unfolded protein response.19
We investigated the biological changes associated
with ambroxol therapy in human participants and its
consequences on the biochemical and clinical markers of
PD. The primary end points were safety and tolerability
of ambroxol therapy, central nervous system penetration,
and change in CSF GCase activity between baseline and
186 days.
Methods
Study Design and Participants
We performed a single-center open-label noncontrolled clini-
cal trial of oral ambroxol therapy (escalating dose to 1.26 g
per day [420 mg 3 times per day]) in patients with PD of mod-
erate severity. The clinical trial was conducted at the Leonard
Wolfson Experimental Neuroscience Centre, a dedicated
clinical research facility at the University College London
Queen Square Institute of Neurology from January 11, 2017,
to April 25, 2018. A clinical trial steering committee provided
clinical oversight. Statistical support was provided by the
Peninsula Clinical Trials Unit of the University of Plymouth in
the United Kingdom. The study was approved by the Institu-
tional Joint Research Office of University College London, the
UK Medicines and Healthcare products Regulatory Agency,
and the London-Bloomsbury Research Ethics Committee.
Written informed consent was obtained from all participants
before study-related procedures were initiated. The study
was conducted in accordance with the ethical principles of
the Declaration of Helsinki26 and the Guideline for Good
Clinical Practice.27 The trial protocol is available in Supple-
ment 1, and a detailed summary of study visits is available in
eTable 1 in Supplement 2.
Patients were recruited from the established research da-
tabases of the National Hospital for Neurology and Neurosur-
gery and the Royal Free London Hospital. Eligible partici-
pants were aged 40 to 80 years, had idiopathic PD as defined
by Queen Square Brain Bank criteria,28 were judged able to self-
administer the clinical trial drug, and were at stage 3 or less
on the Hoehn and Yahr Scale, which classifies the progres-
sion of PD symptoms in 5 stages (stage 1 indicates unilateral
involvement only, and stage 5 indicates wheelchair-bound or
bedridden unless aided). A portion of participants were pre-
selected on the basis of their known GBA1 mutation–carrier
status. Key exclusion criteria included the use of an interven-
tional medicinal product within the last 30 days or exposure
to 3 or more interventional medicinal products within the last
12 months. All participants underwent confirmatory sequenc-
ing of exons 1 to 11 of the GBA1 gene. A full list of exclusion and
Key Points
Question Does ambroxol cross the blood-brain barrier, and what
are the biochemical changes associated with ambroxol therapy
in patients with Parkinson disease with and without
glucocerebrosidase gene mutations?
Findings In this open-label clinical trial of 17 patients with
Parkinson disease, ambroxol crossed the blood-brain barrier and
bound to the β-glucocerebrosidase enzyme, and it increased
β-glucocerebrosidase enzyme protein levels and cerebrospinal
fluid α-synuclein levels in patients both with and without
glucocerebrosidase gene mutations.
Meaning Ambroxol therapy has potential for study as a
neuroprotective compound for the treatment of patients with
Parkinson disease both with and without glucocerebrosidase
gene mutations.
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inclusion criteria can be found in eMethods 2 in Supple-
ment 2.
At the evaluation for clinical trial entry, each patient un-
derwent a physical and neurological examination, an electro-
cardiogram, and blood sampling for clinical laboratory tests.
Women of childbearing age also received a pregnancy test.
After confirmation of patient eligibility, clinical visits were held
at baseline, day 11, day 93, day 186, and day 279, with tele-
phone contact at predetermined intervals (eTable 1 in Supple-
ment 2). In addition to routine clinical blood tests, blood
samples were taken at each assessment. Cerebrospinal fluid
examination was performed at baseline and 186 days, with a
third optional lumbar puncture (LP) at 279 days.
The 186-day exposure period comprised 28 days of dose
escalation, with each dose administered 3 times per day as
follows: 60 mg (days 1-7), 120 mg (days 8-14), 180 mg (days
15-21), and 300 mg (days 22-28). This exposure period was
followed by 158 days of administration of ambroxol at 1.26 g
per day (420 mg 3 times per day). Patients were issued am-
broxol therapy in 2 batches, 1 at baseline and 1 at 93 days.
Ambroxol tablets were donated by PRO.MED.CS Praha a. s.
(Prague, Czech Republic).
All patients were taking dopaminergic therapy, and
levodopa dosage equivalents have been included in Table 1.
Patients attended each visit in an off-medication state, de-
fined as more than 8 hours (overnight) of withdrawal of
levodopa or more than 24 hours of withdrawal of levodopa for
those taking modified-release dopamine agonists.
Assessments were performed between 8 AM and 9 AM by
a single assessor (S.M.). Measurement instruments included
(1) the Movement Disorder Society Unified Parkinson Dis-
ease Rating Scale (MDS-UPDRS; score range, 0-272, with 0
indicating no disability and 272 indicating total disability),
which was administered on days 0, 93, 186, and 279; (2) the
Montreal Cognitive Assessment (MoCA; score range, 0-30,
with ≥26 indicating normal cognitive function), which was
administered on days 0 and 186; (3) the Non-Motor Symp-
toms Scale (NMSS; score range, 0-360, with 0 indicating no
severity and frequency of symptoms and 360 indicating high
severity and frequency of symptoms), which was adminis-
tered on days 0 and 186; and (4) the Non-Motor Symptoms
Questionnaire (NMSQuest; 30 items evaluating the presence
of nonmotor symptoms, with 0 indicating no presence of
symptoms and 30 indicating maximum presence of symp-
toms), which was administered on days 0 and 186.
Empty ambroxol blister packs were collected at 93 and
186 days to assess participant adherence to treatment. All
adverse events (AEs), biochemical results (eTable 2 in
Supplement 2), and measurements of blood pressure, heart
rate, and weight were recorded.
Outcomes
The primary outcomes, all assessed at 186 days, were change
in CSF ambroxol levels and change in CSF GCase activity. The
predefined secondary outcomes, all assessed at 186 days,
were the safety and tolerability of ambroxol in the study
population (measured by the frequency and severity of AEs
and abnormal findings on clinical examinations, blood tests,
or electrocardiograms), the change in blood leucocyte GCase
activity, the change in CSF GCase protein levels, the CSF total
glucosylceramide levels, the CSF and serum α-synuclein lev-
els, and the CSF and serum tau levels. We also recorded the
results of the MoCA, NMSS, and NMSQuest assessments that
were conducted at baseline and 186 days.
Sample Collection, Assays, and Statistics
Cerebrospinal fluid was collected before 10 AM from partici-
pants after they had fasted overnight. Samples were frozen
at –80 °C within 60 minutes of collection in the case of CSF
and within 90 minutes of collection in the case of leucocyte
pellets. Samples were only defrosted immediately before the
performance of assays. Cerebrospinal fluid GCase assays were
all performed within 7 and 14 days of sample collection. Leu-
cocyte GCase assays were performed between 7 and 28 days
of sample collection.
Details of the biochemical assays are provided in eMethods
3 and 4 in Supplement 2.
The statistical analyses followed a predefined statistical
analysis plan written by the clinical trial statisticians (A.H.V.S.
and J. Hosking). As the result of unforeseen circumstances, the
statistician specified in the original protocol was not avail-
able to perform the final analysis. Therefore, a revised statis-
tical analysis plan (eMethods 5 in Supplement 2) was pro-
duced before data analysis was conducted and the study was
completed. All data analyses were performed using Stata soft-
ware, version 14.2 (StataCorp LLC). The distribution of the out-
comes was assessed through inspection of the plotted data
(eFigures 1, 2, and 3 in Supplement 2). For the primary analy-
sis, 95% CIs were presented alongside the results from a 2-sided
t test (significance threshold of P < .05) of the change in CSF
GCase activity. The lower CI and 1-sided t test results (signifi-
cance threshold of P < .05) that were presented for the change
in CSF ambroxol levels reflected the fact that the change was
lower bounded by 0 because of anticipated 0 concentrations












Age, y 60.2 (9.7) 56.1 (9.2) 63.4 (9.2)
Men, No. (%) 15 (83.3) 7 (87.5) 8 (80.0)
Hoehn and Yahr stage, median (range)a 2 (1-3) 2 (1-3) 2 (1-3)
Age at onset, y 51.7 (11.5) 44.5 (7.9) 58.9 (10.2)b
Levodopa equivalence, mg 743 (484) 756 (564) 733 (442)
Abbreviation:
GBA1, glucocerebrosidase gene.
a Recorded in the on state.
b P = .007.
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at baseline. To register as a change, ambroxol concentrations
were required to be greater than the assay limit of detection
of 0.5 ng/mL at 186 days. A descriptive analysis that corre-
lated the change (Pearson coefficient) in ambroxol levels and
the change in CSF GCase activity was also performed. The
changes in secondary outcomes between baseline and 186 days
were presented with 95% CIs. All data analyses were per-
formed from November 1 to December 14, 2018.
Results
A total of 24 patients with moderate PD were evaluated for
study eligibility. Of those, 23 patients entered the Ambroxol
in the Modification of Parkinson Disease study. A total of 18
patients (15 men [83.3%]; mean [SD] age, 60.2 [9.7] years) com-
pleted the study. One patient was excluded after unsuccess-
ful LP attempts that were performed by 2 experienced opera-
tors. Two patients withdrew because they experienced
headaches after LP and before the beginning of ambroxol treat-
ment. One participant withdrew at day 1 after treatment be-
gan, citing the high ambroxol tablet count (21 tablets per day),
and 1 withdrew at 93 days after treatment began, citing fam-
ily illness. Of the 18 patients who completed the study, 1 was
excluded from the CSF analyses (including the primary analy-
sis) because of a red blood cell contamination of more than
500 cells per cm3 in the baseline CSF sample (flow diagram of
participant recruitment and retention in Figure 1).
Participants with GBA1 mutations had the following vari-
ants (an asterisk indicates a phenotype that is known to cause
severe Gaucher disease): p.E326K wild type (3 patients),
p.N370S wild type (1 patient), p.R463C* wild type (2 pa-
tients), p.T369M/p.W393X* (1 patient), and RecNcil (p.L444P,
p.A456P, and p.V460V)* wild type (1 patient).
Seven participants (3 with GBA1 mutations [GBA1+] and 4
without mutations [GBA1–]) underwent a third LP at 279 days.
These 7 participants included the patient who was excluded
from the analyses because of a blood-contaminated baseline
CSF sample. As a result, 18 participants (8 GBA1+ and 10 GBA1–)
were included in blood and clinical analyses at 186 and 279
Figure 1. Flow Diagram of Participant Recruitment and Retention
75 Patients prescreened
24 Evaluated for eligibility
30 Excluded (did not meet 
prescreening criteria)
21 Declined to participate
23 Underwent baseline LP 
(9 GBA1+ and 14 GBA1–)




Excluded (GBA1–; unsuccessful LP) 
Withdrew consent (2 GBA1–)
20 Began ambroxol treatment 
(9 GBA1+ and 11 GBA1–)
2 Withdrew consent (1 GBA1+ and 
1 GBA1–)
18 Completed ambroxol 
treatment and underwent 
LP at 180 days  (8 GBA1+ 
and 10 GBA1–)
18 Attended final study visit 
(8 GBA1+ and 10 GBA1–)
18 Included in final analyses
(8 GBA1+ and 10 GBA1–)
18 Included in blood analyses 
at 180 and 270 days
17 Included in CSF analysis at 
180 days
1 Excluded (GBA1–; CSF blood 
contamination of baseline 
sample)
7 Underwent optional final LP
(3 GBA1+ and 4 GBA1–)
6 Included in CSF analysis at 
270 days
1 Excluded (GBA1–; CSF blood 
contamination of baseline 
sample)
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days. Seventeen participants (8 GBA1+ and 9 GBA1–) were
included in the CSF analyses at 186 days, and 6 participants
(3 GBA1+ and 3 GBA1–) were included in the CSF analyses at
279 days.
Based on the number of empty ambroxol blister packs
collected, we estimated a mean (SD) adherence to treatment
of 89% (13%). Blood and CSF ambroxol levels at baseline
confirmed that no participants had taken the drug before the
treatment start date.
Table 2 shows a summary of results for participants who
completed the study. The results of the GBA1+ and GBA1– sub-
groups are available in eTables 3 and 4 in Supplement 2.
Primary and Secondary Outcomes
Ambroxol was undetectable in blood serum and CSF at base-
line. At day 186, the CSF ambroxol level was 156 ng/mL (95%
lower confidence limit, 129 ng/mL; 1-sided paired t test,
P < .001). At 186 days, the mean (SE) CSF ambroxol levels
were 11% (6%) of the mean blood levels. As anticipated by
our pretrial CSF studies, which indicated inhibition of GCase
in CSF rather than enhancement in tissues, the mean (SE)
CSF GCase activity decreased by 0.059 (0.026) nmol/mL per
hour (95% CI, -0.115 to -0.002; 2-sided paired t test, P = .04;
Figure 2A), which was a 19% reduction from the mean base-
line GCase activity.
The drug was well tolerated, and no serious AEs were re-
ported. A total of 176 AEs occurred, of which 121 were deemed
unrelated, 32 unlikely to be related, 15 possibly related, 5 prob-
ably related, and 3 definitely related to treatment. The AEs
deemed to be probably related to the interventional medicinal
product were nausea (1 patient), vomiting (2 patients), a burn-
ing sensation after swallowing the interventional medicinal
product (1 patient), and loose stool (1 patient). Definitely related
AEs were acid reflux (1 patient), nausea (1 patient), and a tran-
sitory skin condition on the chest, back, and arms (1 patient).
A full list of AEs is available in eTable 5 and a list of recorded AEs
is available in eTable 6 in Supplement 2. A mean (SD) weight loss
of 1.3 (2.5) kg was observed between baseline and 186 days (95%
CI, –2.59 to 0.01). No protocol deviations occurred.
Between baseline and 186 days, mean (SE) increases of 50
(17) pg/mL (13%) in total CSF α-synuclein concentration (95%
CI, 14-87; P = .01; Figure 2B) and 88 (22) pmol/L (35%) in CSF
GCase protein levels (95% CI, 40-137; P = .002; Figure 2C) were
observed. Effect sizes did not indicate a significant change in
CSF tau (mean [SE] change, 5 [8] pg/mL; 95% CI, –7 to 17;
P = .36) or glucosylceramide levels (mean [SE] change, 14 [9]
pmol/L; 95% CI, –6 to 35; P = .16). The correlation between am-
broxol concentration and the change in CSF GCase activity was
not significant (Pearson coefficient, r = –0.161; P = .52). The CSF
analysis of the 6 participants from whom CSF was collected
Table 2. Results of Participants Who Completed the Study
Resulta
Mean (SD)
Baseline Day 11 Day 93 Day 186
Total participants, No.
Blood 18 18 18 18
CSF 17 17 17 17
Ambroxol, ng/mL
Blood serum 0 316 (196) 1084 (396) 1432 (570)b
CSF 0 NA NA 156 (53)b
GCase activity
Blood leucocytes, nmol/mg/h 11.0 (5.2) 12.8 (4.9) 13.1 (4.8) 12.0 (5.2)
CSF, nmol/mL/h 0.309 (0.153) NA NA 0.250 (0.142)b
GCase protein level, pmol/L
CSF 250 (47) NA NA 338 (104)b
α-Synuclein, pg/mL
Blood serum 20 793 (9418) 19 991 (7380) 24 964 (9391) 23 395 (9998)
CSF 383 (103) NA NA 433 (117)b
Tau, pg/mL
Blood serum 1.00 (0.25) 0.84 (0.24) 0.88 (0.22) 0.80 (0.24)b
CSF 206 (59) NA NA 211 (63)
Glucosylceramide, pmol/L
CSF 246 (83) NA NA 260 (80)
MDS-UPDRS score
Part 3 31.1 (14.5) NA 27.2 (10.7) 24.3 (12.1)b
Total 62.6 (32.2) NA 57.7 (27.6) 53.9 (30.3)b
MoCA score 25.0 (4.8) NA NA 26.7 (4.0)
NMSS score 49.3 (36.1) NA NA 60.8 (38.6)b
NMSQuest score 10.6 (6.0) NA NA 10.8 (6.0)
Weight, kg 83 (17) 83 (17) 82 (17) 82 (17)b





Parkinson’s Disease Rating Scale;
MoCA, Montreal Cognitive




a Clinical markers are recorded in the
off state.
b Indicates a significant change from
baseline to 186 days (analyzed by
t test).
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at baseline, 186 days, and 279 days is presented in eTable 4 in
Supplement 2.
Between baseline and 186 days, mean (SE) blood leuco-
cyte GCase activity increased by 1.0 (1.4) nmol/mg/h (95% CI,
–2.0 to 4.0; P = .48) (Table 2 and Figure 2D). Wide variation
was noted in the recorded change in serum α-synuclein con-
centration (mean [SE] change, 2602 [3649] pg/mL; 95% CI,
–4689 to 9893; P = .46), although a mean (SE) decrease of
0.20 (0.08) pg/mL was observed in serum tau levels (95% CI,
–0.37 to -0.05; P = .01).
Between baseline and 186 days, the mean (SD) total MDS-
UPDRS score decreased (ie, improved) by 8.7 (11.8) points (95%
CI, –15.3 to –2.2; P = .01) with a mean (SD) rebound of 7.2 (9.8)
points between 186 and 279 days. This change appeared to be
associated primarily with the MDS-UPDRS part 3 motor score
(score range, 0-56, with 0 indicating no motor impairment and
56 indicating severe motor impairment), which showed a mean
(SD) decrease of 6.8 (7.1) points between baseline and 186 days
(95% CI, –10.4 to –3.1; P = .001) and a mean (SD) increase of 7.6
(7.0) points between 186 and 279 days. Seven of 18 patients in-
creased their dopaminergic therapy during the course of the
study, and the same deflection of MDS-UPDRS changes was ob-
served in those on stable therapy and in those who increased
their medication therapy (eFigures 4 and 5 in Supplement 2).
As anticipated, the change in MoCA scores were skewed
and bound by 0 because of the preponderance of participants
who maintained their scores from baseline. An increase (ie, im-
provement) in the mean (SD) MoCA scores of 1.7 (1.3) points
was recorded between baseline and 186 days. In addition, the
mean (SD) NMSS score increased (ie, worsened) by 11.5 (18.5)
points (95% CI, 2.4-20.8; P = .02), but the mean (SD) change
in the NMSQuest score was only 0.2 (2.6) points (95% CI, –1.5
to 1.0; P = .72) between baseline and 186 days.
In Vitro Assays
Before the clinical trial, we performed in vitro assays to esti-
mate the association of ambroxol, an inhibitory chaperone,
with changes in GCase activity in acellular CSF. We added
500nM (189 ng/mL, chosen on the basis of CSF ambroxol lev-
els reported in a previous clinical trial)17 of ambroxol to
human CSF taken from healthy participants (via diagnostic LPs
for suspected idiopathic intracranial hypertension).




























































































Days After Start of Treatment
A, Box plot with superimposed data points at baseline (median, 0.321;
interquartile range [IQR], 0.142) and 186 days (median, 0.216; IQR, 0.221).
Analysis included 17 participants (8 GBA1+ and 9 GBA1–). Mean (SE) change of
0.059 (0.026) nmol/mL per hour (95% CI, –0.115 to –0.002; 2-sided paired
t test, P = .04) represents a 19% decrease. B, Box plot (median and IQR) with
superimposed data points at baseline and 186 days. Analysis included 17
participants (8 GBA1+ and 9 GBA1–). Mean (SE) change of 50 (17) pg/mL (95%
CI, 14-87; 2-sided paired t test, P = .01) represents a 13% increase. C, Box plot
(median and IQR) with superimposed data points at baseline and 186 days.
Analysis included 17 participants (8 GBA1+ and 9 GBA1–). Mean (SE) change of
88 (22) pmol/L (95% CI, 40-137; 2-sided paired t test, P = .002) represents a
35% increase. All data points are horizontally offset for ease of interpretation.
D, Error bars indicate SE of the mean. Analysis included 18 participants (8 GBA1+
and 10 GBA1–). Mean (SE) change between baseline and 186 days of 1.0 (1.4)
nmol/mg per hour (95% CI, –2.0 to 4.0; P = .48) represents a 9% increase.
CSF indicates cerebrospinal fluid; GBA1-, negative glucocerebrosidase gene;
GBA1+, positive glucocerebrosidase gene; and GCase, glucocerebrosidase
enzyme.
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In addition, we performed a positive control by thermo-
dynamically denaturing and chemically inhibiting GCase with
conduritol B epoxide.29 The experiment comprised 5 techni-
cal repeats for CSF derived from 5 participants for each con-
dition. Compared with the control samples, a mean (SD) de-
crease of 42% (12%) in CSF GCase activity (mean [SD] change
in activity, –0.093 [0.026]; 95% CI, 0.046-0.140 nmol/mL per
hour; P = .01) was observed after the addition of ambroxol. The
denatured and conduritol B epoxide–inhibited samples regis-
tered no residual activity.
Discussion
To our knowledge, this study represents the first clinical trial
of personalized therapy for a stratified (genetically defined)
subtype of PD and the first use of ambroxol therapy in pa-
tients with PD. The study met its primary outcomes, which
were to confirm that ambroxol was able to penetrate CSF and
that it had a modulatory effect on CSF GCase. The finding that
ambroxol penetrates CSF is consistent with a recent clinical trial
of ambroxol (at an equivalent dose) in 5 patients with a mean
age of 18 years who had neuronopathic Gaucher disease.17 Our
study indicates that ambroxol therapy is well tolerated in pa-
tients with PD. This finding is important, as the administered
dose was approximately 10 times higher and was adminis-
tered for a longer duration than specified in its license.
Ambroxol has an inhibitory effect on GCase activity within
acellular human CSF, which is consistent with its known ac-
tivity as an inhibitory chaperone with a neutral pH. Within
largely acellular CSF, the GCase protein is free, which is in con-
trast to its normal intracellular lysosomal location. Ambroxol
is a pH-dependent inhibitory small molecular chaperone that
binds to the active site of the GCase protein and reduces ac-
tivity. Binding enables transportation to the lysosome and elu-
tion of free active enzymes under acidic conditions. There-
fore, in acellular CSF, ambroxol will bind to and inhibit free
GCase. However, in tissues, including those in the brain, am-
broxol will increase intracellular GCase activity, as reported in
studies of rodent and primate models7,8
The sustained upregulation of expression of CSF GCase
protein levels indicates target engagement of ambroxol with
the GCase pathway. The increase in total CSF α-synuclein con-
centration implies, based on previous in vitro and in vivo
data,6-9,11,15 that ambroxol has also had an association with
α-synuclein metabolism. These results suggest an increase in
GCase activity within the brain itself, although this activity
cannot, of course, be measured in vivo. No clear consensus
exists on the association of PD with changes in total CSF
α-synuclein, but reduced levels of total CSF α-synuclein
have been described, while oligomeric and phosphorylated
α-synuclein have increased.30 Ambroxol upregulates the ex-
pression of GCase, probably via the transcription factor EB
pathway, and increases vesicular export.9,23 The increase in CSF
α-synuclein could be interpreted as an increase of extracellu-
lar export of the protein from the brain parenchyma.
Interpretation of the changes in MDS-UPDRS and MoCA
results is difficult in the context of a nonplacebo-controlled
study. However, the changes support the clinical impression
that no substantial deleterious effect of ambroxol was ob-
served among participants taking ambroxol, including any
adverse effect on the motor features of their PD.
Limitations
Our study has several limitations. The sample was relatively
small, although the complexity of the study and its nature as a
proof-of-concept clinical trial were factors in its design. A pla-
cebo arm was not used, so the clinical outcomes should be in-
terpreted with caution. We could have elected to have a more
genetically homogenous GBA1 study group, but this homoge-
neity may have limited the interpretation of the data. The mean
age of our participants was 60.2 years, which is relatively young
for patients with PD. However, this mean age was consistent with
our inclusion criteria of a Hoehn and Yahr stage of 3 or less and
was comparable with many drug intervention studies of pa-
tients with PD. Participants were recruited from databases of pa-
tients with PD with and without GBA1 mutations, but we do not
believe this recruitment method resulted in a bias relevant to
the biochemical biomarkers used as end points in this study.
Conclusions
In conclusion, we confirm that ambroxol has potential as a drug
to target the glucocerebrosidase pathway in PD and increase
GCase activity in the brain. These findings concur with cell and
animal modeling, which indicate that ambroxol modulates
α-synuclein levels. We believe ambroxol therapy has promise
for further investigation as a drug to improve outcomes, par-
ticularly in patients who have PD with a GBA1 mutation and
potentially in those without a GBA1 mutation. Larger placebo-
controlled studies are warranted.
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